WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
China slams U.S.' citing mutual defense treaty to back Philippine provocations in South China SeaChangbai Mountain transforms into a winter paradiseDPRK top leader attends special concert by Chinese traditional orchestraChina's top political advisory body concludes standing committee sessionTexas, Arizona migrant laws for border are dealt setbacksState secrets law revised to handle online leaksXinjiang to open up further to world despite West's smearingChinese Embassy deplores Romania's rejection of Huawei's 5G equipment authorizationSaudi students taking classes in MandarinEco park adjacent to residential buildings enables villagers to enjoy scenic views
2.3778s , 6574.78125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Worldly Wonders news portal